Idel Therapeutics closed a €9 million seed round (about $10.4 million) to develop an intracellular delivery technology aimed at getting cytotoxic drugs into the cytosol of tumor cells. The company framed its approach as a way to reach intracellular targets that are difficult to drug with conventional extracellular delivery methods. The funding supports further validation of the delivery system and progression toward clinical-enabling work. Idel’s focus on cytosolic delivery also speaks to a broader push across oncology for delivery technologies that can increase payload efficacy while controlling safety.